Stocks and Investing
Stocks and Investing
Mon, November 7, 2016
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Christopher Raymond Upgraded (BIIB) to Buy on, Nov 7th, 2016
Christopher Raymond of Piper Sandler, Upgraded "Biogen Inc." (BIIB) to Buy on, Nov 7th, 2016.
Christopher has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Eun Yang of "Jefferies" Maintained at Hold with Decreased Target to $316 on, Wednesday, October 5th, 2016
This is the rating of the analyst that currently disagrees with Christopher
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $368 on, Wednesday, August 17th, 2016
Contributing Sources